Product
Alglucosidase alfa
Aliases
alglucosidase alfa, ALGLUCOSIDASE ALFA, Alglucosidase alfa GZ419829, Alglucosidase alfa (GZ419829), Lumizyme (2 other aliases)
Name
Lumizyme
INN Name
ALGLUCOSIDASE ALFA
FDA Approved
Yes
6 clinical trials
1 organization
3 indications
1 document
Indication
Pompe DiseaseIndication
Pompe's DiseaseIndication
Glycogen Storage DiseaseClinical trial
A Prospective Observational Study to Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)Status: Recruiting, Estimated PCD: 2026-03-30
Clinical trial
A Single Arm, Prospective, Open-label, Multi-center Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa TreatmentStatus: Active (not recruiting), Estimated PCD: 2024-07-25
Clinical trial
A Sub-Registry to Determine the Presence of Alglucosidase Alfa in Breast Milk From Women With Pompe Disease Treated With Alglucosidase Alfa.Status: Completed, Estimated PCD: 2024-02-09
Clinical trial
A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Avalglucosidase Alfa (neoGAA, GZ402666) and Alglucosidase Alfa in Treatment naïve Patients With Late-onset Pompe DiseaseStatus: Completed, Estimated PCD: 2020-03-19
Clinical trial
A Global Prospective Observational Registry of Patients With Pompe DiseaseStatus: Recruiting, Estimated PCD: 2034-12-20
Clinical trial
An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of Avalglucosidase Alfa (NeoGAA, GZ402666) in Patients With Infantile-onset Pompe Disease Treated With Alglucosidase Alfa Who Demonstrate Clinical Decline or Sub-optimal Clinical ResponseStatus: Active (not recruiting), Estimated PCD: 2019-09-30
Document
DailyMed Label: LumizymeOrganization
Genzyme Corporation